Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erymeto ICU gastric retention protocol study
NL-OMON58356Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of erythromycin and metoclopramide in gastroparesis and feeding intolerance, sponsored by Erasmus MC. Primary endpoint: Change in gastric residual volume over time. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
erythromycinmetoclopramide
03
Conditions
gastroparesisfeeding intolerance
Beyond the preview
Go deeper on NL-OMON58356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58356.